Carbamazepine with Methylene Blue Interaction Details


Brand Names Associated with Carbamazepine

  • Carbamazepine
  • Carbatrol®
  • Epitol®
  • Equetro®
  • Tegretol®
  • Tegretol®-XR
  • Teril®

Medical Content Editor
Last updated Nov 25, 2023


Curious for more information about this interaction?

Ask our pharmacists directly!

Reach out to us

Interaction Effect

An increased risk of serotonin syndrome (hypertension, hyperthermia, myoclonus, mental status changes)


Interaction Summary

Concurrent administration or overlapping therapy with carbamazepine and an MAOI, including methylene blue, is contraindicated and may result in serotonin syndrome, a hyperserotonergic state characterized by symptoms such as agitation and restlessness, myoclonus, changes in mental status, hyperreflexia, diaphoresis, shivering, and tremor. Serious, even fatal, reactions have been reported with concomitant use of serotonin-specific reuptake inhibitors and MAOIs. A minimum of 14 days should elapse after discontinuing an MAOI before initiating therapy with carbamazepine. If concomitant use of carbamazepine with IV methylene blue is required, choose the lowest possible dose of methylene blue and monitor the patient closely for CNS effects for up to 4 hours after methylene blue administration 


Severity

Contraindicated


Onset

Unspecified


Evidence

Theoretical


How To Manage Interaction

Concurrent use of carbamazepine and an MAOI, including methylene blue, is contraindicated. Wait at least 14 days after discontinuing an MAOI before initiating carbamazepine. If concomitant use of carbamazepine with IV methylene blue is required, choose the lowest possible dose of methylene blue and monitor the patient closely for CNS effects for up to 4 hours after methylene blue administration .


Mechanism Of Interaction

Unknown

Carbamazepine Overview

  • Carbamazepine is used alone or in combination with other medications to control certain types of seizures in people with epilepsy. It is also used to treat trigeminal neuralgia (a condition that causes facial nerve pain). Carbamazepine extended-release capsules (Equetro brand only) are also used to treat episodes of mania (frenzied, abnormally excited or irritated mood) or mixed episodes (symptoms of mania and depression that happen at the same time) in patients with bipolar I disorder (manic-depressive disorder; a disease that causes episodes of depression, episodes of mania, and other abnormal moods). Carbamazepine is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain.

See More information Regarding Carbamazepine

Return To Our Drug Interaction Homepage


Feedback, Question Or Comment About This Information?

Ask , our medical editor, directly! He's always more than happy to assist.


Definitions

Severity Categories

Contraindicated

These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.


Major

This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.


Moderate

This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.


Minor

While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.


Onset

Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.

Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.


Evidence

Level of documentation of the interaction.

Established: The interaction is documented and substantiated in peer-reviewed medical literature.

Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.


How To Manage The Interaction

Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.

It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.


Mechanism Of Interaction

The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.


Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.

Where Does Our Information Come From?

Information for our drug interactions is compiled from several drug compendia, including:

The prescribing information for each drug, as published on DailyMED, is also used. 

Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.

The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.